Medindia
Medindia LOGIN REGISTER
Advertisement

Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference

Friday, November 14, 2008 General News
Advertisement
SAN DIEGO, Nov. 13, 2008 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Lazard Capital Markets Healthcare Conference in New York on Wednesday, November 19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will be providing a corporate overview.
Advertisement



The live presentation will be Web cast, and a recording will be made available following the event. The Web cast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live Web cast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
Advertisement



About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.





SOURCE Amylin Pharmaceuticals, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close